Mesoblast (ASX:MSB) Share Price and News - StockTrack

Market Cap (1-Jul) $2,136,106,496 (333rd)	Close (30-Jun) $1.14 0 (0%)	Volume (30-Jun) 2,606,681	Shortsold (19-Jun) 79,324,475 (6.21%) (26th)
52w High $3.37	52w Low $0.88	P/E 454.55	EPS -0.15

	Subject
	MSB MSB Ann: MSB Q3 Financial Results and Operational Highlights
	1 (current) 2 3
	MSB MSB Ann: Third Quarter Financial Results on Form 6-K
	MSB MSB Ann: Mesoblast Q3 Financial Results Webcast
	MSB MSB Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients
	MSB MSB Ann: Ceasing to be a substantial holder
	MSB MSB Ann: Becoming a substantial holder
	MSB MSB Ann: Litigation Update
	MSB MSB Ann: Ceasing to be a substantial holder
	MSB MSB Ann: Ceasing to be a substantial holder
	MSB MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	MSB MSB Ann: Becoming a substantial holder
	MSB MSB Ann: Appendix 3G and Appendix 3H
	MSB MSB Ann: Company Secretary Appointment
	MSB MSB Ann: Becoming a substantial holder
	MSB MSB Ann: Initial Director's Interest Notice
	MSB MSB Ann: Director Appointment
	MSB MSB Ann: S&P DJI Announces March 2022 Quarterly Rebalance
	MSB MSB Ann: Final Director's Interest Notice
	MSB MSB Ann: MSB Q2 Financial Results and Operational Highlights
	MSB MSB Ann: Second Quarter Results Presentation
	MSB MSB Ann: Half Yearly Report and Accounts
	MSB MSB Ann: Mesoblast Q2 Financial Results Webcast
	MSB MSB Ann: Ulcerative Colitis & Crohns Results Presented at ECCO
	MSB MSB Ann: Mesoblast Appoints Dr Eric Rose as Chief Medical Officer
	MSB MSB Ann: Appendix 4C Quarterly Activity Report
	MSB MSB Ann: MSB Presents at Edison Group Global Healthcare Conference
	MSB MSB Ann: Cleansing Notice and Appendix 2A
	MSB MSB Ann: Proposed issue of securities - MSB
	MSB MSB Ann: Appendix 3G, Appendix 3H and Appendix 3Y
	MSB MSB Ann: 36-Month Results of Phase 3 Trial in Chronic Low Back Pain
	MSB MSB Ann: Biotech Showcase 2022 Presentation
	MSB MSB Ann: Prospectus for Warrants Related to Oaktree Debt Refinance
	MSB MSB Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD
	MSB MSB Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
	MSB MSB Article: Mesoblast shares tank as Novartis terminates deal
	MSB MSB Article: ASX overcomes Woolies, Mesoblast sell-off to close flat
	MSB MSB Ann: Update on Novartis Agreement
	MSB MSB Ann: Pause in Trading
	MSB MSB Ann: Rexlemestrocel Greatest Benefit in Diabetics and Ischemics
	MSB MSB Ann: Global CardioVascular Clinical Trialists Forum Presentation
	MSB MSB Ann: Results of Meeting
	MSB MSB Ann: CEO Presentation to 2021 Annual General Meeting
	MSB MSB Ann: Mesoblast Chairman Message to 2021 AGM
	MSB MSB Ann: MSB Q1 Financial Results and Operational Highlights
	MSB MSB Ann: First Quarter Results Presentation
	MSB MSB Ann: First Quarter Financial Results on Form 6-K
	MSB MSB Ann: Mesoblast Q1 Financial Results Webcast
	MSB MSB Ann: MSB and Oaktree Conclude Refinancing of Senior Debt Facility
	MSB MSB Ann: Proposed issue of securities - MSB
	MSB MSB Article: Mesoblast surge guides ASX to small rise

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

End of Day Prices

Date	Close	Volume	Change
30-Jun	$1.66	3,610,556	+0.01 (0.30%)
27-Jun	$1.65	2,962,048	+0.03 (1.85%)
26-Jun	$1.62	3,894,010	+0.05 (2.86%)
24-Jun	$1.58	4,377,040	+0.01 (0.64%)
23-Jun	$1.57	4,545,261	-0.08 (4.57%)
20-Jun	$1.64	14,156,741	-0.03 (1.80%)
19-Jun	$1.67	7,144,969	-0.12 (6.70%)
18-Jun	$1.79	6,671,859	-0.07 (3.76%)
16-Jun	$1.86	4,404,185	+0.07 (3.62%)
13-Jun	$1.80	4,018,872	-0.06 (2.97%)
12-Jun	$1.85	3,728,210	+0.10 (5.41%)
06-Jun	$1.76	2,396,730	-0.02 (0.85%)
05-Jun	$1.77	2,707,464	+0.03 (1.72%)
04-Jun	$1.74	6,727,183	+0.13 (7.74%)
03-Jun	$1.62	3,753,078	+0.02 (1.25%)
9 up, 6 down, and 0 flat days

High $1.17	Low $1.13	Trades 1,304	Turnover $2,983,889	Volume 2,606,681
30 June 2023 at 4:10pm

High $1.17	Low $1.13	Trades 1,304	Turnover $2,983,889	Volume 2,606,681
30 June 2023 at 4:10pm

Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology

$1.14 -0.01 (-0.44%)

$1.14 -0.01 (-0.44%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Mesoblast Health Care Biopharmaceuticals Cancer Medicine Oncology

$1.14 -0.01 (-0.44%)

$1.14 -0.01 (-0.44%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology